查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1978271

全球mRNA疫苗市场规模、份额、趋势和成长分析报告（2026-2034年）

Global mRNA Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 107 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

mRNA疫苗市场预计将从2025年的127.6亿美元成长到2034年的274.3亿美元，2026年至2034年的复合年增长率为8.88%。

由于传讯RNA（mRNA）疫苗的成功研发和应用，全球mRNA疫苗市场正迅速成长。这类疫苗利用遗传讯息刺激人体免疫系统，使其辨识并对抗特定病原体。 mRNA技术在全球疫苗接种宣传活动中的有效性显着提升了人们对这种创新疫苗研发方法的兴趣。製药公司和研究机构正大力投资mRNA平台，以开发针对多种感染疾病的疫苗。

推动市场成长的另一个关键因素是mRNA疫苗研发的柔软性和速度。与传统疫苗技术不同，mRNA平台能够快速适应并针对新的病毒及其变种。这项特性在应对新出现的健康威胁方面极为宝贵。递送系统和储存技术的进步也提高了mRNA疫苗的稳定性和分发效率，从而促进了其在全球的应用。

未来，mRNA市场预计将从感染疾病预防扩展到癌症免疫疗法和个人化医疗等领域。目前正在进行的研究和临床试验正在探索基于mRNA的疗法在多种疾病治疗中的潜力。随着生物技术的不断创新，mRNA技术有望成为下一代医疗疗法的关键组成部分。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球mRNA疫苗市场：依应用划分

  • 市场分析、洞察与预测
  • 癌症
  • 感染疾病
  • 其他（自体免疫疾病）

第五章 全球mRNA疫苗市场：依最终用户划分

  • 市场分析、洞察与预测
  • 政府机构
  • 私人医院和诊所
  • 其他（研究机构、製药公司、生技公司等）

第六章 全球mRNA疫苗市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第七章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第八章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Pfizer Inc
    • Moderna Inc
    • Novartis AG
    • Sanofi
    • Arcturus Therapeutics
    • Gennova Biopharmaceuticals Ltd
    • Aimei Vaccine Co. Ltd
简介目录
Product Code: VMR112114452

The mRNA Vaccine Market size is expected to reach USD 27.43 Billion in 2034 from USD 12.76 Billion (2025) growing at a CAGR of 8.88% during 2026-2034.

The global mRNA vaccine market has grown rapidly due to the successful development and deployment of messenger RNA-based vaccines. These vaccines use genetic instructions to stimulate the body's immune system to recognize and fight specific pathogens. The effectiveness of mRNA technology during global vaccination campaigns has significantly increased interest in this innovative approach to vaccine development. Pharmaceutical companies and research organizations are investing heavily in mRNA platforms to develop vaccines for a variety of infectious diseases.

Another major factor driving market growth is the flexibility and speed of mRNA vaccine development. Unlike traditional vaccine technologies, mRNA platforms can be quickly adapted to target new viruses or variants. This capability makes them highly valuable in responding to emerging health threats. Advances in delivery systems and storage technologies are also improving the stability and distribution of mRNA vaccines, supporting broader adoption worldwide.

In the future, the market is expected to expand beyond infectious disease prevention into areas such as cancer immunotherapy and personalized medicine. Ongoing research and clinical trials are exploring the potential of mRNA-based treatments for a wide range of diseases. As biotechnology innovation continues to progress, mRNA technology is likely to become a major component of next-generation medical therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

  • Cancer
  • Infectious Disease
  • Others (Autoimmune Diseases)

By End-user

  • Government Entities
  • Private Hospitals & Clinics
  • Others (Research Institutes, Pharmaceutical and Biotechnology Companies, etc.)

COMPANIES PROFILED

  • Pfizer Inc, Moderna Inc, Novartis AG, Sanofi, Arcturus Therapeutics, Gennova Biopharmaceuticals Ltd, Aimei Vaccine Co Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA VACCINE MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Application
  • 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Others (Autoimmune Diseases) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MRNA VACCINE MARKET: BY END-USER 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast End-user
  • 5.2. Government Entities Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Private Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Others (Research Institutes, Pharmaceutical and Biotechnology Companies, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MRNA VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.2.1 By Application
    • 6.2.2 By End-user
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.3.1 By Application
    • 6.3.2 By End-user
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.4.1 By Application
    • 6.4.2 By End-user
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.5.1 By Application
    • 6.5.2 By End-user
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 6.6.1 By Application
    • 6.6.2 By End-user
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL MRNA VACCINE INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Pfizer Inc
    • 8.2.2 Moderna Inc
    • 8.2.3 Novartis AG
    • 8.2.4 Sanofi
    • 8.2.5 Arcturus Therapeutics
    • 8.2.6 Gennova Biopharmaceuticals Ltd
    • 8.2.7 Aimei Vaccine Co. Ltd